

# WHO Drug Information

## Contents

### General Policy Topics

- The rational development  
of therapeutic management 1

### Regulatory Matters

- Acitretin: avoidance of pregnancy 6  
Anabolic steroids: enhanced control measures 6  
Paediatric anti-diarrhoeal preparations withdrawn 6  
Beclobrate: risk of hepatitis 7  
Canthaxanthin: disallowed as an active  
ingredient 7  
Counterfeit drugs: remedial measures 8  
Glafenine: withdrawal on grounds of safety 8  
Metipranolol eyedrops: granulomatous  
anterior uveitis 8  
Organ extracts: dangers of allergenicity  
and infection 8  
Propaphenone: fatal dysrhythmias 9  
Trolamine: concerns regarding potential  
carcinogenicity 9  
Urocanic acid: discontinuation of use in  
sunscreens 9  
Urokinase: not for embolic stroke 9  
Water-soluble gums: danger of  
oesophageal obstruction 10

### Advisory Notices

- Anticonvulsants and lymphadenopathy 11  
Kelp in herbal medicines:  
danger of hyperthyroidism 11  
Nonsteroidal anti-inflammatory agents:  
hazards of long-term use 11  
Drug-induced ototoxicity 12  
Penicillamine and myasthenia gravis 12  
Parenteral cytotoxic preparations: dangers of  
intrathecal injection 12  
First-dose reactions to trimethoprim 12

### Update on AIDS

- HIV infection 14  
Zidovudine 17  
Associated infections 20  
Aciclovir 26  
Amphotericin B 27  
Calcium folinate 28  
Codeine 28  
Fluconazole 29  
Ganciclovir 29  
Ketoconazole 30  
Nystatin 31  
Pentamidine 31  
Pyrimethamine 32  
Sulfadiazine 32  
Sulfamethoxazole/trimethoprim 33

### Recent Publications

- The evaluation of carcinogenic risks:  
selected pharmaceuticals 37